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license (http://creativebiomarker platform designed for neurodegenerative disease research following an integrative
approach.
Methods: Participants of the SPIN cohort provide informed consent to donate blood and cerebrospi-
nal fluid samples, receive detailed neurological and neuropsychological evaluations, and undergo a
structural 3T brainMRI scan. A subset also undergoes other functional or imaging studies (video-pol-
ysomnogram, 18F-fluorodeoxyglucose PET, amyloid PET, Tau PET). Participants are followed annu-
ally for a minimum of 4 years, with repeated cerebrospinal fluid collection and imaging studies
performed every other year, and brain donation is encouraged.
Results: The integration of clinical, neuropsychological, genetic, biochemical, imaging, and neuro-
pathological information and the harmonization of protocols under the same umbrella allows the dis-
covery and validation of key biomarkers across several neurodegenerative diseases.
Discussion: We describe our particular 10-year experience and how different research projects were
unified under an umbrella biomarker program, which might be of help to other research teams pur-
suing similar approaches.o competing interests to declare that are relevant for *Corresponding author. Tel.: 134935565986; Fax: 134935568604.
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Biomarkers have revolutionized our conceptualization of
neurodegenerative diseases. In recent years, advances in the
field of biomarkers have been instrumental in understanding
the neurobiology underlying these disorders. Currently, bio-
markers are essential to define the long preclinical stages, to
achieve early diagnosis, to improve the selection of partici-
pants in clinical trials and to monitor the effect of drugs tar-
geted to specific pathological pathways [1,2]. In the Sant Pau
Memory Unit, as in many other teams specialized in
neurodegenerative diseases, we have progressively adapted
our clinical routine and research programs to incorporate
the different biomarkers that are developed in the field. In
this article, we describe our particular experience with this
process and how the different research projects were
unified under an umbrella biomarker program, which
might be of help to other research teams pursuing similar
approaches.
The Sant Pau Memory Unit is part of the Neurology
Department at the Hospital de la Santa Creu i Sant Pau, a ter-
tiary center that offers medical care to an area in Barcelona
of approximately 400,000 inhabitants. In addition, the Unit
is a referral center for complex or atypical cases around
the Catalonia region. The Sant Pau Memory Unit attends pa-
tients with cognitive or behavioral symptoms referred either
by their primary care physician or by other neurologists to
receive specialized diagnosis and treatment and/or to facili-
tate their participation in research protocols.
Patients receive a standard initial medical visit by one of
our faculty or fellow neurologists. Our initial visit consists of
an extensive medical history revision, physical examination,
and the administration of brief tests and questionnaires to
assess cognition and functional impact in daily living activ-
ities. In most cases, in particular when cognitive impairment
is not evident, a formal 1-hour cognitive evaluation by a
neuropsychologist is scheduled, and sometimes, especially
in patients with a suspected frontotemporal lobar
degeneration–related syndrome or an atypical Alzheimer’s
disease (AD) syndrome, a specialized 2-hour additional visit
helps to refine their clinical diagnosis. Neuroimaging and
blood tests are also usually scheduled if they have not
been previously ordered by their referral physician. In
2009, the clinical protocol was refined and cerebrospinal
fluid (CSF) biomarkers were integrated to improve the early
detection of prodromal AD. This approach facilitates the im-
plementation of disease-modifying drugs that are currently
under investigation in phase 2 or phase 3 clinical trials. After
the completion of these tests, a follow-up visit is scheduledwhere results are discussed, diagnosis is disclosed, and an
appropriate treatment is prescribed, if necessary. Patients
and/or caregivers, usually receive an appointment with a
nurse to enhance the understanding of treatment posology
and eventually to clarify other medical, legal, or social as-
pects related to the disease.
As shown in Fig. 1, once the standard care has been
ensured, most patients are invited to participate in research,
either by enrolling in clinical trials involving new investiga-
tional drugs or in any of our observational research studies.
Clinical trials are managed by a specific research team
composed of neurologists, neuropsychologists, a research
nurse, and a data manager. This team reviews inclusion/
exclusion criteria and organizes follow-up appointments
and drug administration according to each specific trial pro-
tocol. Participants of our observational studies, on the other
hand, may receive ancillary biomarker and/or imaging tests
and a specialized additional visit where supplementary ques-
tionnaires and cognitive/behavioral scales are administered.
Our observational research studies include different neuro-
degenerative conditions and were recently reorganized un-
der a global umbrella study named SPIN (Sant Pau
Initiative on Neurodegeneration).2. Methods
2.1. The SPIN cohort: General protocol
The SPIN cohort study was launched in 2011 as an um-
brella program with the aim of grouping individual clinical
observational studies performed in the Sant Pau Memory
Unit. The SPIN cohort currently includes cognitively normal
participants, patients with subjective cognitive decline, mild
cognitive impairment, mild AD dementia, frontotemporal
lobar degeneration–related syndromes (FTLD-S), dementia
with Lewy bodies (DLB) and Down syndrome (which is
treated in a separate section; see DABNI project). Inclusion
and exclusion criteria for the SPIN cohort are detailed in
Table 1. Patients with FTLD-S are systematically referred
to the Motor Neuron Disease Clinic at the Neuromuscular
Diseases Unit and evaluated by neurologists experienced
in diagnosis and management of motor neuron diseases. A
standardized visit is performed focusing on the detection
of signs and symptoms suggestive of upper and lower motor
neuron involvement. In these patients, an electrophysiolog-
ical evaluation, including electromyographic concentric
needle examination, motor and sensory nerve conduction
studies are performed by qualified physicians according to
established standards.
Primary care physician Neurologists
• Extensive medical history revision
• Physical examinaon
• Brief tests to assess cognion and 
funconal impact in daily living 
acvies
Standard neuropsychological evaluaon
Neuroimaging: brain scan or MRI
General blood tests
Lumbar puncture for CSF biomarkers
• Results discussion
• Diagnosis disclosure
• Prescripon of appropriate treatmentNurse appointment
Roune clinical
follow-up
Pharmacological clinical trials
Observaonal research studies
Clinical trials team
SPIN cohort protocol
Sant Pau Memory Unit
Inial medical visit
Follow-up visit
Are you interested in our
research programs?
No Yes
Supplementary clinical and 
neuropsychological protocol if necessary
Fig. 1. Flow-chart of clinical practice and research protocols in the Sant Pau Memory Unit.
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discovery and validation, consent for blood and CSF collec-
tion is required for all participants. Detailed neurological
and neuropsychological evaluation and a structural 3T brain
MRI are also necessary for inclusion. As shown in Fig. 2, a
subset of participants receive a video-polysomnogram and/
or imaging tests that involve radiotracers, such as 18F-fluoro-
deoxyglucose (18FDG), amyloid or Tau PET. Participants
are followed on an annual basis for a minimum of 4 years,
and we offer the possibility to repeat imaging and/or CSF
studies every two years.2.2. Cognitively normal volunteers
Asymptomatic volunteers are an extremely relevant
group in the SPIN cohort. Volunteers are usually spouses
or children of patients that are informed about our studies
at the outpatient clinics of the Sant Pau Memory Unit. Vol-
unteers can also learn about our projects through talks, our
website (https://santpaumemoryunit.com) or social media
(@SantPauMemory).
All volunteers receive an initial consultation with a
neurologist in which the SPIN protocol is explained in detail,
inclusion/exclusion criteria are reviewed and informed con-
sent is signed. As in other observational studies, the SPIN
cohort has a blinded design and biomarker results are not
disclosed to volunteers unless clinically relevant or in case
the participant becomes eligible for pharmacological pre-
vention clinical trials.On the first day, a neurologist and a neuropsychologist
perform a full medical history review, physical examina-
tion, and a standard neuropsychological evaluation
(Table 2) followed by a lumbar puncture and blood extrac-
tion. Neuroimaging studies might be scheduled on
different days.
To minimize the impact of the study on volunteers’
routine, all participants can choose how they prefer to be
informed of the results, either by post, email, or by sched-
uling an extra on-site appointment. Those participants
whose neuropsychological evaluation, biochemical analysis,
or neuroimaging studies show clinically relevant abnormal
results are scheduled for an on-site consultation to discuss
these results. Cognitively normal participants are contacted
annually for a minimum of 4 years, and they are invited to
repeat neuropsychological, imaging, and CSF studies every
two years.2.3. Ethical aspects
At the moment of inclusion in our observational
studies, the details of the protocol are explained, and ver-
bal and signed informed consent is obtained from all par-
ticipants. We specifically ask all participants for their
consent to the acquisition, analysis, and storage of biolog-
ical samples. They are also informed about the possibility
of sharing anonymized information and/or biological sam-
ples with other researchers, which is requested in an inde-
pendent consent form. The original protocol and the
Table 1
Inclusion and exclusion criteria for the SPIN cohort
Inclusion criteria
For all participants
18 years or older
Signed informed consent
Cognitively normal controls
No memory complaints
MMSE [27–30]
CDR global score 5 0
FCSRT total immediate score (EAS62)  7
Absence of significant impairment in other domains or in daily living activities.
Subjective cognitive decline
Memory complaints (severe enough to have resulted in a request for medical referral)
MMSE [27–30]
CDR global score 5 0
FCSRT total immediate score (EAS62)  7
Absence of significant impairment in other domains or in daily living activities.
Prodromal AD
MMSE [24–30]
CDR global score 5 0.5
Absence of a clinical diagnosis of dementia
CSF biomarkers supporting AD pathophysiology
Typical AD dementia
CDR global score  0.5
FCSRT total immediate score (EAS62)  6
Clinical criteria of “probable AD dementia with evidence of the AD pathophysiological process” [59]
Dementia with Lewy bodies
Lewy body dementia: probable Lewy body dementia [60] or Lewy body mild cognitive impairment: Mild cognitive impairment [61] AND one or more of:
- Visual hallucinations
- Parkinsonism
- REM sleep behavior disorder
- Cognitive fluctuations [62]
Frontotemporal lobar degeneration–related syndromes (FTLD-S)
Possible, probable, or definitive behavioral variant of frontotemporal dementia [63]
Semantic variant of primary progressive aphasia [64]
Nonfluent/agrammatic variant of primary progressive
aphasia [64]
Corticobasal syndrome [65]
Progressive supranuclear palsy syndromes [66,67]
Any of the clinical diagnoses along the amyotrophic lateral sclerosis–frontotemporal dementia (ALS-FTD) continuum [68,69]
Down syndrome
Presence of trisomy at chromosome 21
Exclusion criteria
 Inability to complete neuropsychological tests and questionnaires (illiteracy, blindness, hearing impairment)
 Contraindication for MRI (claustrophobia, pacemaker, aneurism clips, cardiac mechanical valve)
 Contraindication for lumbar puncture (anticoagulation, coagulation disease): Must not be taking anticoagulant treatment such as acenocoumarol, heparin,
warfarin, dabigatran, rivaroxaban, apixaban
 Current treatment with drugs that can impair cognition
 Medical history of:
B Neurological disease (stroke, brain lesions, epilepsy)
B Psychiatric disease (psychosis or major depression)
B Drug abuse in the last year
B Medical history of cancer is an exclusion criterion when:
- It affects the central nervous system
- It has not been in complete remission for 5 years or longer
- Patient has received potentially neurotoxic chemotherapy
- Patient has received cranial radiotherapy
Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid; EAS62, education-adjusted score at the age of 62 years [70]; MMSE, Mini–Mental State
Examination; CDR, Clinical Dementia Rating; FCSRT, Free and Cued Selective Reminding Test; SPIN, Sant Pau Initiative on Neurodegeneration.
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SPIN cohort protocol BASELINE YEAR 1 YEAR 2 YEAR 3 YEAR 4
Revision of inclusion and exclusion criteria Required - - - -
Protocol revision and general consent signature Required - - - -
Medical history revision Required Update Update Update Update
Clinical examinaon Required - Required - Required
Neuropsychological evaluaon Required Required Required - Required
General blood test Required Required Required - Required
Blood extracon for plasma/serum/genecs Required - Oponal - Oponal
Lumbar puncture for CSF biomarkers Required - Oponal - Oponal
Brain MRI Required - Oponal - Oponal
18F-Fluorodeoxyglucose PET Oponal - Oponal - Oponal
Amyloid PET Oponal - Oponal - Oponal
Tau PET Oponal - Oponal - Oponal
Sleep evaluaon and real world evidence data Oponal - Oponal - Oponal
SPI  cohort protocol BASELINE YEAR 1 YEAR 2 YEAR 3 YEAR 4
Fig. 2. General protocol in the SPIN cohort. Abbreviations: SPIN, Sant Pau Initiative on Neurodegeneration.
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ethics committee. The SPIN cohort is based on blinded
enrollment and only clinically relevant biomarker results
are disclosed.2.4. Neuropsychological evaluation
All participants in the SPIN cohort receive a standard
one-hour neuropsychological evaluation to assess episodic
verbal memory, visual memory, attention, executive func-
tions, visuospatial, visuoperceptive and visuoconstructive
functioning and language. Neuropsychiatric symptoms,
functional impact, and the level of global cognitive impair-
ment are also assessed. Table 2 lists all tests included in
our standard neuropsychological evaluation [3].
Our standard protocol includes two verbal memory tests
that are sequentially administered to maximize the detection
of prodromal AD: the Free and Cued Selective Reminding
Test (FCSRT) and, after a nonverbal interference task, the
Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD) word list when the former is within normal range.
We have found that the combination of these two tests can
improve the early detection of AD and define prognostic pro-
files in mild cognitive impairment [3].
Participants with a diagnosis of DLB or FTLD-S receive
an additional neuropsychological evaluation to further
investigate cognitive functions that are particularly impaired
in these disorders, such as visuoperceptive functions and
fluctuations in DLB or language, behavior, and executive
functions in FTLD-S (Table 2).2.5. Cerebrospinal fluid
Lumbar puncture for CSF sampling is required for all par-
ticipants of the SPIN cohort. CSF is collected and processed
in polypropylene tubes following international recommen-
dations [4,5]. The first 2 ml of CSF are transferred to the
general laboratory for cell count, and analysis of glucose
and protein levels. Another volume of 15-20 ml is
transferred to our laboratory where samples are processed
and aliquoted within the first two hours after the lumbar
puncture. Aliquots are stored at 280C until analysis. Full
protocol for CSF processing is detailed in Fig. 3A.
Core AD biomarkers (Ab1-42, t-Tau, and p-Tau) are
routinely measured in all participants. Our clinical cutoffs
for core AD biomarkers were initially obtained from a group
of 70 patients clinically diagnosed with dementia of the Alz-
heimer type (whose clinical diagnoses were made blind to
biomarker results) and 45 age-matched cognitively normal
controls. Our internal cutoffs were calculated using ELISA
[6], transferred to fully automated platforms and validated
in a sample of patients that underwent amyloid PET [7].
Our laboratory participates in the Alzheimer’s Association
quality control program for CSF biomarkers [8,9].
2.6. Blood and DNA extraction
All participants in the SPIN cohort have blood drawn at
the time of lumbar puncture. Fasting is not required before
the extraction, but the time from last meal to blood extrac-
tion is recorded. All samples are transferred to our laboratory
where they are centrifuged and aliquoted within 2 hours after
Table 2
Clinical and neuropsychological evaluation protocols
Standard neuropsychological evaluation
Screening tests
Mini–Mental State Examination [71,72]
Memory Alteration Test [73]
Episodic verbal memory*
Free and Cued Selective Reminding Test (FCSRT) [70,74]
Consortium to Establish a Registry for Alzheimer’s Disease (CERAD)
word list [75]
Visual memory
Complex Rey Figure Recall [70,76,77]
Geometric Figures recall from the Consortium to Establish a Registry for
Alzheimer’s Disease or CERAD battery [75]
Attention/executive functions
Phonemic verbal fluency test [78,79]
Trail-Making test form A and B [80]
WAIS Direct and Reverse Digit span [80]
Clock Drawing Task on command [81]
Language
Boston naming test [82,83]
Consortium to Establish a Registry for Alzheimer’s Disease or CERAD
battery (orders comprehension) [75,84]
Semantic verbal fluency [78,79]
Visuospatial/visuopercetpive/visuoconstructional functioning
Geometric figures copy subtest of CERAD
Number location subtest from the Visual Object Space and Perception
(VOSP) battery [85]
Poppelreuter overlapping figures test [86]
Neuropsychiatric symptoms
Neuropsychiatric inventory [87]
Geriatric depression scale [88]
Functional assessment
Interview for deterioration in daily living in dementia [89]
Global cognitive impairment
Global deterioration scale [90]
Clinical dementia rating [91]
FTLD-specific Clinical Dementia Rating [92]
Additional neuropsychological evaluation in LBD patients
Visual Object Space and Perception (VOSP) battery [85]
Line Orientation Test
Facial Recognition Test
Pareidolia Test
Clinician Assessment of Fluctuation
Additional clinical and neuropsychological evaluation in FTLD-S patients
Standardized neurological examination (CATFI protocol) including
UPDRS-III [93]
Separate clinical interview with at least 1 reliable informant for a precise
determination of the chronology of both cognitive and behavioral signs
and symptoms [94]
Frontotemporal Dementia Rating Scale [95,96]
In ALS-FTD patients: Edinburgh Cognitive and Behaviour ALS Screen
(ECAS) [97,98]
Extensive language evaluation (audio recorded)
Progressive Aphasia Language Scale [99,100]
Spontaneous speech and description of Boston cookie theft picture test
[84]
Standardized examination of Apraxia of Speech including alternating
movement rate and sequential motion rate tasks [101]
Repetition of sentences and pseudowords [84]
Syntactic processing [84]
Pyramid palm and trees test [102,103]
(Continued )
able 2
linical and neuropsychological evaluation protocols (Continued )
dditional clinical and neuropsychological evaluation in FTLD-S patients
Extended phonemic verbal fluency test [78,79]
Narrative writing of the Boston cookie theft picture [84] and free
extensive narrative writing without time constraints (1 full A4 page)
Spanish adaptation of the New Adult Reading Test named “Test de
acentuacion de palabras” [104]
ttention/executive functions
Design fluency of the D-KEFS battery [105]
Stroop test [106]
Frontal Assessment Battery [107]
ehavior and mood
Frontal Behavioral Inventory [108]
Informant version of the Lille Apathy Rating Scale [109]
Cambridge Behavioral Inventory Revised [110]
Brief questionnaire of Socioemotional Dysfunction
Abbreviations: ALS-FTD, amyotrophic lateral sclerosis–frontotemporal
ementia; FTLD-S, frontotemporal lobar degeneration–related syndromes;
ATFI, Catalan Initiative for Frontotemporal Dementia; UPDRS-III, Uni-
ed Parkinson’s Disease Rating Scale, Part III (motor examination).
*Tests that assess episodic verbal memory are administered sequentially
eparated by a nonverbal interference task.
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extraction and stored at 280C until they need to be
analyzed. Full protocol for blood processing is detailed in
Fig. 3B.
DNA is extracted from whole blood samples using the
DNeasy Blood & Tissue kit (Qiagen). APOE genotype is
routinely determined for all participants in the SPIN cohort
by direct DNA sequencing of exon 4 and visual analysis of
the resulting electropherogram is performed to identify the
two coding polymorphisms that encode the three possible
apoE isoforms. Other genetic studies in the SPIN cohort
involve mendelian genes related to neurodegenerative de-
mentias (i.e., PSEN1, PSEN2, APP, C9orf72, MAPT, VCP,
etc.), as well as other genes and genomic regions that have
been involved in their genetic architecture, such as TREM2
[10], CHCHD10 [11], TUBA4A [12], or the 17q21.31 region
around MAPT [13]. High-throughput genotyping and next-
generation sequencing technologies are also used in specific
studies [14,15].2.7. Structural, diffusion, and functional MRI
All participants in the SPIN cohort are required to un-
dergo 3T-MRI for structural, diffusion, and resting-state
functional MRI. Acquisitions parameters are detailed in
Table 3.
Our neuroimaging core takes advantage of surface-based
methodologies to process MRI images. Structural MRI is
processed using FreeSurfer software package (v6.0; http://
surfer.nmr.mgh.harvard.edu) to obtain individuals’ cortical
reconstruction and cortical thickness maps by using previ-
ously described methods [16]. Estimated surfaces are then
inspected to detect possible errors in the automatic segmen-
tation procedure, and manual edits are performed to guar-
antee an accurate cortical segmentation.
2 x 10 ml CSF 
Sarstedt 10ml
Ref. 62.610.018
Centrifuge
2000g x 10min
4ºC
3ml 
Aliquot 270ul (10)
STORE -80ºC until analysis
Lumbar puncture
1 ml CSF 
regular tube 
(green cap)
•Cell count
•Glucose
•Proteins
SARSTEDT 2ml
REF. 72.694.007
polypropylene
LABEL E
100 / 250 / 500ul CSF
Rest 
Aliquot 500ul (12)
1ml 
Aliquot 120ul (8)
Local laboratory Alzheimer laboratory
A
3 x 10ml
Centrifuge
2000g x 10min 
4ºC
Alliquot
STORE -80ºC until analysis
Blood extraction
SARSTEDT 1.5ml
REF. 72.690.001
8 x 10ml whole blood
4 x 10ml
EDTA
1 x 10ml
Genetics Biomarkers
DNA and RNA extraction
PLASMA PELLET 
(EDTA)
LABEL A
480ul 
plasma
+20uL Prot 
inhibitor (2)
LABEL C
500ul pellet    
(4)
LABEL 
B
120 ul 
plasma 
(5)
Vortex x 10sec
and alliquot
1 x 10ml 
serum
1 x 10ml
SERUM
LABEL D
500ul serum 
(>7)
Alliquot
LABEL 
B
270ul 
plasma 
(8)
LABEL 
B
500ul 
plasma 
(>10)
1 x 10ml
RNA
1 x 10ml
1 x 10ml
EDTA
1 x 10ml 
serum Local Laboratory
B
Fig. 3. Biofluid processing: protocols for cerebrospinal fluid (A) and blood (B).
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house developed algorithm [17,18] based on FSL (http://
fsl.fmrib.ox.ac.uk/fsl/fslwiki) and FreeSurfer tools. Our
pipeline computes cortical diffusivity metrics that allow
the evaluation of microstructural changes in the cortex,
mitigating some of the pitfalls caused by usual voxel-
based methodologies. Resting-state functional MRI studies
are processed with an in-house algorithm specifically devel-
oped for these sequences [19]. This pipeline admits proced-
ures commonly used in functional imaging studies such as
seed analysis and independent component analysis.
2.8. Nuclear medicine imaging: 18FDG PET, amyloid
PET, Tau PET
Studies with 18FDG PET are acquired in a subset of par-
ticipants to measure brain metabolism. These studies arevisually rated by an expert in nuclear medicine, and images
are also processed and quantified by our neuroimaging team.
For the whole-brain voxelwise analysis, 18FDG PET images
are intensity-scaled by the reference pons-vermis region,
spatially normalized using SPM12 (http://www.fil.ion.ucl.
ac.uk/spm/) to the Montreal Neurological Institute PET tem-
plate and spatially smoothed with a Gaussian kernel of full
width at half maximum 8 mm. All resulting images are visu-
ally inspected to check for possible registration errors. The
quantitative analysis of 18FDG uptake in a specific region
of interest is performed following themethodology proposed
by Landau et al. [20–22].
Over the past few years, new tracers have been developed
to visualize in vivo specific neuropathological aggregates. In
the SPIN cohort, amyloid PET studies with 18F-florbetapir
have been acquired for a subset of participants, and more
recently, we have incorporated 18F-flutemetamol and tau
Table 3
MRI acquisition parameters for structural, diffusion, and functional MRI
MRI acquisition parameter Structural T1 MRI Diffusion-weighted imaging MRI Resting-state functional MRI
Protocol MPRAGE Echo-planar Imaging Echo-planar Imaging
Repetition Time (ms) 8.1 13,677 200
Echo Time (ms) 3.7 61 31
Slices 160 80 21
Slice thickness (mm) 1 2 4 (1 of gap)
Voxel Size (mm) 0.94!0.94!0.94 2!2!2 2.4!3.3!4
Specific Parameters - Single b 5 0 image. 32 gradient directions
with b 5 1000. One inverted phase
encoding b 5 0
190 volumes. Eyes open.
Abbreviation: MPRAGE, magnetization-prepared rapid acquisition with gradient echo.
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icine, and specifically developed semiautomated quantifica-
tion protocols are applied [7]. Briefly, amyloid PET images
are spatially normalized to the subject’s T1-MRI and then to
the Montreal Neurological Institute 152 template using the
individual’s anatomical MRI coregistration. Global amyloid
PET standardized uptake value ratio scores are estimated
averaging frontal, cingulate, parietal, and temporal cortices
and using the whole cerebellum as the reference region
[23]. In addition to the commonly used analyses in PET us-
ing voxel-based and region-based approaches, we have
added surface-based methodologies that substantially
improve the reliability of PET effects and reduce the inter-
subject variance.2.9. Sleep evaluation and real-world evidence data
Cognitively normal volunteers in the SPIN cohort and
participants with Down syndrome are invited to undergo a
full sleep evaluation with subjective and objective measures
of the nocturnal sleep and the circadian sleep-wake pattern.
This evaluation includes an interview with a sleep specialist,
a full nocturnal video-polysomnography, and actigraphy.
Participants are requested to track their sleep-wake pattern
in sleep diaries and to answer sleep questionnaires designed
to assess participants’ self-reported sleep quality (Pittsburgh
Sleep Quality Index), somnolence (Epworth Sleepiness
Scale) and to identify participants at risk for sleep apnea syn-
drome (Berlin Questionnaire). Video-polysomnography
studies are performed in individual, sound-attenuated,
temperature-regulated sleep unit rooms under continuous
supervision of qualified technical staff. All-night video-pol-
ysomnography records information from 19 electroencepha-
lographic channels, two oculographic electrodes, four
surface electromyographic channels, and six sensors to
monitor respiratory function by assessing oximetry, oronasal
airflow, thoracoabdominal movements, and snoring detec-
tion. The week before the polysomnography, participants
wear an actigraph in the nondominant arm to monitor rest/
activity cycles. These portable devices record data on levels
of daily activity and light during 24 hours. They provide in-
formation about total sleep time and sleep efficiency that canbe compared with subjective sleep diary reports and objec-
tive polysomnographic data.2.10. Neuropathology
All participants in the SPIN cohort are encouraged to con-
sent for brain donation. In follow-up visits, we stress the
importance of neuropathological studies to advance the
research of neurodegenerative diseases and suggest all par-
ticipants contact the Barcelona’s Neurological Tissue Bank
(http://www.clinicbiobanc.org) for formal registration.
Neuropathological validation is a critical issue in multi-
modal biomarker studies. Brain donation not only allows
the confirmation of the diagnosis and the presence of comor-
bid pathologies but is also necessary to correlate patholog-
ical data with CSF or imaging biomarkers [24] and to
characterize the underlying biological processes of these
biomarkers [25]. Moreover, it is known that secondary pa-
thologies can influence the biomarker signatures [26,27],
and it is important to capture them for their correct
interpretation.
In our group, we have implemented array tomography
microscopy, which is based on obtaining ultrathin (70 nm)
consecutive brain sections combined with immunofluores-
cence [28,29]. Array tomography requires special fixation
conditions, which limits the availability of samples for this
type of study. This technique has been previously applied
to successfully evidence synaptic abnormalities in AD and,
more recently, in DLB [30–33].2.11. Data integration
One of the strengths of the Sant Pau Memory Unit is that
we have integrated clinical, neuropsychological, biomarker,
genetic, neuroimaging, and neuropathological information
from subjects with different neurodegenerative disorders in
one single database. Every participant receives a unique
code to integrate all the information. As all data are associ-
ated to specific time points for each participant, information
from different categories can easily be combined, and auto-
mated ready-to-analyze anonymized datasheets can be ob-
tained.
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Initiative: DABNI
The Alzheimer-Down Unit was founded in 2014 as an
alliance between the Sant Pau Memory Unit and the Down
Syndrome Catalan Foundation. The specific purpose of
this Unit, the first of its kind in the world, is the assessment
of adults with Down syndrome by medical professionals
specialized in dementia for the detection of AD. This multi-
disciplinary Unit, formed by neurologists, neuropsycholo-
gists and social workers, has been recognized by the
Catalan government as the reference hospital in Catalonia
for the assessment of neurological disorders associated
with Down syndrome.
Taking advantage of the SPIN cohort structure, the
Alzheimer-Down Unit launched a parallel comprehensive
biomarker study entitled “Down-Alzheimer Barcelona Neu-
roimaging Initiative” (DABNI). The aim of the DABNI proj-
ect is to improve our understanding of the mechanisms that
drive AD in Down syndrome (http://fcsd.org/).3. Results
Our database includes neuropsychological data of more
than 6000 participants, genetics data of more than 3200 par-
ticipants, more than 2600 blood samples from 2100 partici-
pants, and more than 2000 CSF samples from 1700
participants. Neuroimaging information of over 1100 MRI
studies, more than 800 FDG-PET and 200 amyloid PET
are also incorporated and matched to clinical, neuropsycho-
logical, genetic, and biomarker information.
CSF samples from the SPIN cohort have contributed to
several international multicenter CSF biomarker studies
[34–38]. The SPIN cohort has contributed to the
characterization of different CSF biomarkers such as b-site
APP-cleaving enzyme activity [39,40], sAPP-b [6,39,41],
neurofilament light chain [41], YKL-40 [6,39,41–43],
progranulin [44], a panel of synaptic proteins [45], and mito-
chondrial DNA [46] in different neurodegenerative diseases.
In addition, the collection of paired blood and CSF samples
offers the possibility to investigate the correlation of
biomarker levels between these two compartments [15,44].
In addition, our DNA repository has been involved in
many international studies aimed at identifying the genetic
basis of neurodegenerative disorders [47–50].
Imaging MRI studies acquired in the SPIN cohort have
contributed to multicenter collaborative studies [17,42,51],
and their combination with other biomarkers has yielded
relevant results regarding multimodal relationships
[41,42,44]. Our neuroimaging team has also developed and
described novel methods for the detection of longitudinal
changes in cortical structure [52] and cortical microstruc-
tural changes in diffusion-weighted sequences in AD and
FTLD-S [17]. Nuclear medicine imaging studies have also
contributed to several international multicenter imaging
biomarker initiatives [53–57].The incorporation of sleep evaluations in some of the
SPIN cohort clinical groups has yielded clinically relevant
results. For example, in participants with Down syndrome,
questionnaires do not completely reflect sleep disturbances
detected on polysomnography, and data acquired by actigra-
phy might be more sensitive to detect daytime sleep
compared with self-reported scales [58].
Access to brain tissue in subjects with antemortem
imaging or with biofluid biomarkers also offers the possibil-
ity to look into innovative clinical-pathological correlations.
The addition of a sophisticated neuropathological quantita-
tive technique such as array tomography microscopy to a
multimodal biomarker program has opened the possibility
of correlating biomarkers with detailed neuropathological
traits. As an example, in the future, we could correlate amy-
loid load measured by amyloid PET with synaptic densities
in different brain regions or a synaptic protein in CSF with
synaptic densities postmortem.
4. Discussion
The organization of the Sant Pau Memory Unit is in many
aspects similar to other units across the globe. However, there
are some key aspects that are specific to our Unit and that
may have been instrumental in achieving certain objectives.
First, the current size of our unit (around 35 members) al-
lows daily interaction and collaboration under a manageable
environment. Larger organizations tend to divide into
smaller groups, hampering daily interaction and limiting
the possibilities of collaboration. Also, the research cores,
such as genetics, biofluid, imaging, or neuropathology, are
developed inside the Unit, which facilitates the flow of pro-
jects and collaborations. Second, our projects are performed
in a highly multidisciplinary environment that facilitates
cross-fertilization and the generation of new ideas. Third,
our members hold a collaborative spirit and share leadership.
The experience and knowledge of consolidated researchers
are complemented by fresh and innovative approaches of
younger researchers. Finally, our hospital environment pro-
vides our research with a clinical patient-focused perspec-
tive, which helps in keeping a holistic view on
neurodegenerative diseases.
The SPIN cohort is a multimodal biomarker platform de-
signed to study neurodegenerative diseases under a holistic
approach. The integration of clinical, neuropsychological,
genetic, biochemical, imaging, and neuropathological infor-
mation and the harmonization of protocols under the same
umbrella has allowed the discovery and validation of key
biomarkers for these diseases. The data generated are crucial
to understanding the pathophysiology of neurodegenerative
diseases and to improve their diagnostic and prognostic
assessment.
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1. Systematic review: Literature was reviewed through
PubMed and meeting abstracts. In the past decade,
different research teams have launched multimodal
biomarker cohorts to improve diagnosis in neurode-
generative diseases. We provide extensive references
for the specific protocols and methods used in the
SPIN cohort.
2. Interpretation: The integration of clinical, neuropsy-
chological, genetic, biochemical, imaging, and
neuropathological information and the harmoniza-
tion of protocols under the same umbrella allows
the discovery and validation of key biomarkers
across several neurodegenerative diseases. We
describe our particular 10-year experience and how
different research projects were unified under an
umbrella biomarker program, which might be of help
to other research teams pursuing similar approaches.
3. Future directions: Longitudinal integrative data in
the SPIN cohort will be of help to further understand
the pathophysiology of neurodegenerative diseases
and to improve their diagnostic and prognostic
assessment.References
[1] Lewczuk P, Riederer P, O’Bryant SE, Verbeek MM, Dubois B,
Visser PJ, et al. Cerebrospinal fluid and blood biomarkers for neuro-
degenerative dementias: An update of the Consensus of the Task
Force on Biological Markers in Psychiatry of the World Federation
of Societies of Biological Psychiatry. World J Biol Psychiatry
2018;19:244–328.[2] Lleo A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK,
Andreasen N, et al. Cerebrospinal fluid biomarkers in trials for Alz-
heimer and Parkinson diseases. Nat Rev Neurol 2015;11:41–55.
[3] Sala I, Illan-Gala I, Alcolea D, Sanchez-Saudinos MB, Salgado SA,
Morenas-Rodrıguez E, et al. Diagnostic and prognostic value of the
combination of two measures of verbal memory in mild cognitive
impairment due to Alzheimer’s disease. J Alzheimer’s Dis 2017;
58:909–18.
[4] Del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S,
Hampel H, Simonsen AH, et al. Recommendations to standardize
preanalytical confounding factors in Alzheimer’s and Parkinson’s
disease cerebrospinal fluid biomarkers: an update. Biomark Med
2012;6:419–30.
[5] Vanderstichele HMJ, Janelidze S, Demeyer L, Coart E, Stoops E,
Herbst V, et al. Optimized standard operating procedures for the anal-
ysis of cerebrospinal Fluid Ab42 and the ratios of Ab isoforms using
low protein binding tubes. J Alzheimers Dis 2016;53:1121–32.
[6] Alcolea D, Martınez-Lage P, Sanchez-Juan P, Olazaran J, Antunez C,
Izagirre A, et al. Amyloid precursor protein metabolism and inflam-
mation markers in preclinical Alzheimer disease. Neurology 2015;
85:626–33.
[7] Alcolea D, Pegueroles J, Mu~noz L, Camacho V, Lopez-Mora D,
Fernandez-Leon A, et al. Agreement of amyloid PET and CSF bio-
markers for Alzheimer’s disease on Lumipulse. Ann Clin Transl Neu-
rol 2019;6:1815–24.
[8] Mattsson N, Andreasson U, Persson S, Arai H, Batish SD,
Bernardini S, et al. The Alzheimer’s Association external quality
control program for cerebrospinal fluid biomarkers. Alzheimer’s De-
ment 2011;7:386–395.e6.
[9] Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S,
Chalbot S, et al. CSF biomarker variability in the Alzheimer’s Asso-
ciation quality control program. Alzheimer’s Dement 2013;
9:251–61.
[10] Ruiz A, Dols-Icardo O, Bullido MJ, Pastor P, Rodrıguez-
Rodrıguez E, Lopez de Munain A, et al. Assessing the role of the
TREM2 p.R47H variant as a risk factor for Alzheimer’s disease
and frontotemporal dementia. Neurobiol Aging 2014;35:e1–4.
[11] Dols-Icardo O, Nebot I, Gorostidi A, Ortega-Cubero S, Hernandez I,
Rojas-Garcıa R, et al. Analysis of the CHCHD10 gene in patients
with frontotemporal dementia and amyotrophic lateral sclerosis
from Spain. Brain 2015;138:e400.
[12] Dols-Icardo O, Iborra O, Valdivia J, Pastor P, Ruiz A, Lopez de
Munain A, et al. Assessing the role of TUBA4A gene in frontotem-
poral degeneration. Neurobiol Aging 2016;38:215.e13–215.e14.
[13] Cervera-Carles L, Pagonabarraga J, Pascual-Sedano B, Pastor P,
Campolongo A, Fortea J, et al. Copy number variation analysis of
the 17q21.31 region and its role in neurodegenerative diseases. Am
J Med Genet B Neuropsychiatr Genet 2016;171:175–80.
[14] Dols-Icardo O, Garcıa-Redondo A, Rojas-Garcıa R, Borrego-
Hernandez D, Illan-Gala I, Mu~noz-Blanco JL, et al. Analysis of
known amyotrophic lateral sclerosis and frontotemporal dementia
genes reveals a substantial genetic burden in patients manifesting
both diseases not carrying the C9orf72 expansion mutation. J Neurol
Neurosurg Psychiatry 2018;89:162–8.
[15] Fortea J, Carmona-Iragui M, Benejam B, Fernandez S, Videla L,
Barroeta I, et al. Plasma and CSF biomarkers for the diagnosis of Alz-
heimer’s disease in adults with Down syndrome: a cross-sectional
study. Lancet Neurol 2018;17:860–9.
[16] Fischl B, Dale AM. Measuring the thickness of the human cerebral
cortex from magnetic resonance images. Proc Natl Acad Sci U S A
2000;97:11050–5.
[17] Montal V, Vilaplana E, Alcolea D, Pegueroles J, Pasternak O,
Gonzalez-Ortiz S, et al. Cortical microstructural changes along the
Alzheimer’s disease continuum. Alzheimer’s Dement 2018;
14:340–51.
[18] Illan-Gala I, Montal V, Borrego-Ecija S, Vilaplana E, Pegueroles J,
Alcolea D, et al. Cortical microstructure in the behavioural variant
D. Alcolea et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 597-609 607of frontotemporal dementia: looking beyond atrophy. Brain 2019;
142:1121–33.
[19] Mandelli ML, Vilaplana E, Brown JA, Hubbard HI, Binney RJ,
Attygalle S, et al. Healthy brain connectivity predicts atrophy pro-
gression in non-fluent variant of primary progressive aphasia. Brain
2016;139:2778–91.
[20] Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM,
Foster NL, et al. Associations between cognitive, functional, and
FDG-PET measures of decline in AD and MCI. Neurobiol Aging
2011;32:1207–18.
[21] Sampedro F, Vilaplana E, de Leon MJ, Alcolea D, Pegueroles J,
Montal V, et al. APOE-by-sex interactions on brain structure and
metabolism in healthy elderly controls. Oncotarget 2015;
6:26663–74.
[22] Suarez-Calvet M, Camacho V, Gomez-Anson B, Anton S, Vives-
Gilabert Y, Dols-Icardo O, et al. Early cerebellar hypometabolism
in patients with frontotemporal dementia carrying the C9orf72
expansion. Alzheimer Dis Assoc Disord 2015;29:353–6.
[23] Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA,
Jagust WJ, et al. Amyloid-b imaging with Pittsburgh compound B
and florbetapir: comparing radiotracers and quantification methods.
J Nucl Med 2013;54:70–7.
[24] Irwin DJ, Lleo A, Xie SX, McMillan CT, Wolk DA, Lee EB, et al.
Ante mortem cerebrospinal fluid tau levels correlatewith postmortem
tau pathology in frontotemporal lobar degeneration. Ann Neurol
2017;82:247–58.
[25] Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, San Martın-
Paniello C, Clarimon J, Belbin O, et al. YKL-40 (Chitinase 3-like
I) is expressed in a subset of astrocytes in Alzheimer’s disease and
other tauopathies. J Neuroinflammation 2017;14:118.
[26] Toledo JB, Brettschneider J, Grossman M, Arnold SE, Hu WT,
Xie SX, et al. CSF biomarkers cutoffs: the importance of coincident
neuropathological diseases. Acta Neuropathol 2012;124:23–35.
[27] Lleo A, Irwin DJ, Illan-Gala I, McMillan CT,Wolk DA, Lee EB, et al.
A 2-Step cerebrospinal algorithm for the selection of frontotemporal
lobar degeneration subtypes. JAMA Neurol 2018;75:738–45.
[28] Micheva KD, Smith SJ. Array tomography: a new tool for imaging
the molecular architecture and ultrastructure of neural circuits.
Neuron 2007;55:25–36.
[29] Kay KR, Smith C, Wright AK, Serrano-Pozo A, Pooler AM,
Koffie R, et al. Studying synapses in human brain with array tomog-
raphy and electron microscopy. Nat Protoc 2013;8:1366–80.
[30] Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW,
Mielke ML, Garcia-Alloza M, et al. Oligomeric amyloid beta associ-
ates with postsynaptic densities and correlates with excitatory syn-
apse loss near senile plaques. Proc Natl Acad Sci U S A 2009;
106:4012–7.
[31] Koffie RM, Hashimoto T, Tai H-C, Kay KR, Serrano-Pozo A,
Joyner D, et al. Apolipoprotein E4 effects in Alzheimer’s disease
are mediated by synaptotoxic oligomeric amyloid-b. Brain 2012;
135:2155–68.
[32] Colom-Cadena M, Pegueroles J, Herrmann AG, Henstridge CM,
Mu~noz L, Querol-Vilaseca M, et al. Synaptic phosphorylated
a-synuclein in dementia with Lewy bodies. Brain 2017;
140:3204–14.
[33] Jackson RJ, Rudinskiy N, HerrmannAG, Croft S, Kim JM, Petrova V,
et al. Human tau increases amyloid b plaque size but not amyloid b-
mediated synapse loss in a novel mouse model of Alzheimer’s dis-
ease. Eur J Neurosci 2016;44:3056–66.
[34] Bos I, Vos SJ, Fr€olich L, Kornhuber J, Wiltfang J, Maier W, et al. The
frequency and influence of dementia risk factors in prodromal Alz-
heimer’s disease. Neurobiol Aging 2017;56:33–40.
[35] Suarez-Calvet M, Kleinberger G, Araque Caballero MA, Brendel M,
Rominger A, Alcolea D, et al. sTREM2 cerebrospinal fluid levels are
a potential biomarker for microglia activity in early-stage Alz-
heimer’s disease and associate with neuronal injury markers.
EMBO Mol Med 2016;8:466–76.[36] Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E,
Cuyvers E, et al. TREM2 mutations implicated in neurodegeneration
impair cell surface transport and phagocytosis. Sci Transl Med 2014;
6:243ra86.
[37] Duits FH, Martinez-Lage P, Paquet C, Engelborghs S, Lleo A,
Hausner L, et al. Performance and complications of lumbar puncture
in memory clinics: Results of the multicenter lumbar puncture feasi-
bility study. Alzheimer’s Dement 2016;12:154–63.
[38] Kruse N, Persson S, Alcolea D, Bahl JMC JMC, Baldeiras I,
Capello E, et al. Validation of a quantitative cerebrospinal fluid
alpha-synuclein assay in a European-wide interlaboratory study.
Neurobiol Aging 2015;36:2587–96.
[39] Alcolea D, Carmona-Iragui M, Suarez-Calvet M, Sanchez-
Saudinos MB, Sala I, Anton-Aguirre S, et al. Relationship between
b-secretase, inflammation and core cerebrospinal fluid biomarkers
for Alzheimer’s disease. J Alzheimers Dis 2014;42:157–67.
[40] Pera M, Alcolea D, Sanchez-Valle R, Guardia-Laguarta C, Martı C-
C, Badiola N, et al. Distinct patterns of APP processing in the CNS in
autosomal-dominant and sporadic Alzheimer disease. Acta Neuropa-
thol 2013;125:201–13.
[41] Alcolea D, Vilaplana E, Suarez-Calvet M, Illan-Gala I, Blesa R,
Clarimon J, et al. CSF sAPPb, YKL-40, and neurofilament light in
frontotemporal lobar degeneration. Neurology 2017;89:178–88.
[42] Alcolea D, Vilaplana E, Pegueroles J, Montal V, Sanchez-Juan P,
Gonzalez-Suarez A, et al. Relationship between cortical thickness
and cerebrospinal fluid YKL-40 in predementia stages of Alz-
heimer’s disease. Neurobiol Aging 2015;36:2018–23.
[43] Illan-Gala I, Alcolea D, Montal V, Dols-Icardo O, Mu~noz L, de
Luna N, et al. CSF sAPPb, YKL-40, and NfL along the ALS-FTD
spectrum. Neurology 2018;91:e1619–28.
[44] Morenas-Rodrıguez E, Cervera-Carles L, Vilaplana E, Alcolea D,
Carmona-Iragui M, Dols-Icardo O, et al. Progranulin protein levels
in cerebrospinal fluid in primary neurodegenerative dementias. JAlz-
heimers Dis 2016;50:539–46.
[45] Lleo A, Nu~nez-Llaves R, Alcolea D, Chiva C, Balateu-Pa~nos D, Co-
lom-Cadena M, et al. Changes in synaptic proteins precede neurode-
generation markers in preclinical Alzheimer’s disease cerebrospinal
fluid. Mol Cell Proteomics 2019;18:546–60.
[46] Cervera-Carles L, Alcolea D, Estanga A, Ecay-Torres M, Izagirre A,
Clerigue M, et al. Cerebrospinal fluid mitochondrial DNA in the
Alzheimer’s disease continuum. Neurobiol Aging 2017;
53:192.e1–192.e4.
[47] Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez DG, Orme T,
Eicher JD, et al. Investigating the genetic architecture of dementia
with Lewy bodies: a two-stage genome-wide association study. Lan-
cet Neurol 2018;17:64–74.
[48] Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N,
Jakobsdottir J, et al. Rare coding variants in PLCG2, ABI3, and
TREM2 implicate microglial-mediated innate immunity in Alz-
heimer’s disease. Nat Genet 2017;49:1373–84.
[49] De Roeck A, Van den Bossche T, van der Zee J, Verheijen J, De
Coster W, Van Dongen J, et al. Deleterious ABCA7 mutations and
transcript rescue mechanisms in early onset Alzheimer’s disease.
Acta Neuropathol 2017;134:475–87.
[50] Heilmann S, Drichel D, Clarimon J, Fernandez V, Lacour A,
Wagner H, et al. PLD3 in non-familial Alzheimer’s disease. Nature
2015;520:E3–5.
[51] Cantero JL, Atienza M, Sanchez-Juan P, Rodriguez-Rodriguez E,
Vazquez-Higuera JL, Pozueta A, et al. Cerebral changes and disrup-
ted gray matter cortical networks in asymptomatic older adults at risk
for Alzheimer’s disease. Neurobiol Aging 2018;64:58–67.
[52] Pegueroles J, Vilaplana E, Montal V, Sampedro F, Alcolea D, Car-
mona-Iragui M, et al. Longitudinal brain structural changes in pre-
clinical Alzheimer’s disease. Alzheimer’s Dement 2017;13:499–509.
[53] Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der
Flier WM, van Berckel BNM, et al. Prevalence of Amyloid PET Pos-
itivity in Dementia Syndromes. JAMA 2015;313:1939–49.
D. Alcolea et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 597-609608[54] Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL,
Engelborghs S, et al. Prevalence of the apolipoprotein E ε4 allele
in amyloid b positive subjects across the spectrum of Alzheimer’s
disease. Alzheimer’s Dement 2018;14:913–24.
[55] Jansen WJ WJ, Ossenkoppele R, Knol DL DL, Tijms BM BM,
Scheltens P, Verhey FRJ FRJ, et al. Prevalence of Cerebral Amyloid
Pathology in Persons Without Dementia. JAMA 2015;313:1924–38.
[56] Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O,
Klunk WE, et al. Association of Cerebral Amyloid-b Aggregation
With Cognitive Functioning in Persons Without Dementia. JAMA
Psychiatry 2018;75:84.
[57] Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendonça A,
OttoM, et al. Pittsburgh compound B imaging and cerebrospinal fluid
amyloid-b in a multicentre European memory clinic study. Brain
2016;139:2540–53.
[58] Gimenez S, Videla L, Romero S, Benejam B, Clos S, Fernandez S,
et al. Prevalence of sleep disorders in adults with Down syndrome:
a comparative study of self-reported, actigraphic, and polysomno-
graphic findings. J Clin Sleep Med 2018;14:1725–33.
[59] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR,
Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s dis-
ease: recommendations from the National Institute on Aging-Alz-
heimer’s Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimer’s Dement 2011;7:263–9.
[60] McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H,
et al. Diagnosis and management of dementia with Lewy bodies:
third report of the DLB Consortium. Neurology 2005;65:1863–72.
[61] Petersen RC. Mild cognitive impairment as a diagnostic entity. J
Intern Med 2004;256:183–94.
[62] Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG,
O’Brien JT, et al. The Clinician Assessment of Fluctuation and the
One Day Fluctuation Assessment Scale. Two methods to assess fluc-
tuating confusion in dementia. Br J Psychiatry 2000;177:252–6.
[63] Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH,
Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the be-
havioural variant of frontotemporal dementia. Brain 2011;
134:2456–77.
[64] Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M,
Cappa SF, et al. Classification of primary progressive aphasia and its
variants. Neurology 2011;76:1006–14.
[65] Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B,
et al. Criteria for the diagnosis of corticobasal degeneration.
Neurology 2013;80:496–503.
[66] Boxer AL, Yu J-T, Golbe LI, Litvan I, Lang AE, H€oglinger GU. Ad-
vances in progressive supranuclear palsy: new diagnostic criteria,
biomarkers, and therapeutic approaches. Lancet Neurol 2017;
16:552–63.
[67] H€oglinger GU. Is it useful to classify progressive supranuclear palsy
and corticobasal degeneration as different disorders? No.MovDisord
Clin Pract 2018;5:141–4.
[68] Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of
Neurology Research Group on Motor Neuron Diseases. El Escorial
revisited: revised criteria for the diagnosis of amyotrophic lateral
sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord
2000;1:293–9.
[69] Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P,
Snowden J, et al. Amyotrophic lateral sclerosis - frontotemporal
spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyo-
troph Lateral Scler Front Degener 2017;18:153–74.
[70] Pena-Casanova J, Gramunt-Fombuena N, Quinones-Ubeda S, San-
chez-Benavides G, Aguilar M, Badenes D, et al. Spanish Multicenter
Normative Studies (NEURONORMA Project): norms for the Rey-
Osterrieth complex figure (copy and memory), and free and cued se-
lective reminding test. Arch Clin Neuropsychol 2009;24:371–93.
[71] Blesa R, Pujol M, Aguilar M, Santacruz P, Bertran-Serra I,
Hernandez G, et al. Clinical validity of the “mini-mental state”for Spanish speaking communities. Neuropsychologia 2001;
39:1150–7.
[72] FolsteinMF, Folstein SE,McHugh PR.Mini-mental state. A practical
method for grading the cognitive state of patients for the clinician. J
Psychiatr Res 1975;12:189–98.
[73] Rami L, Molinuevo JL, Sanchez-Valle R, Bosch B, Villar A.
Screening for amnestic mild cognitive impairment and early Alz-
heimer’s disease with M@T (Memory Alteration Test) in the primary
care population. Int J Geriatr Psychiatry 2007;22:294–304.
[74] Buschke H. Cued recall in amnesia. J Clin Neuropsychol 1984;
6:433–40.
[75] Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A. Con-
sortium to establish a registry for Alzheimer’s disease (CERAD) clin-
ical and neuropsychological assessment of Alzheimer’s disease.
Psychopharmacol Bull 1988;24:641–52.
[76] Rey A. L’examen psychologique dans les cas d’encephalopathie trau-
matique. Arch Psychol 1941:286–340.
[77] Osterreith P. Le test de copie d’une figure complexe: Contribution a
l’etude de la perception et la memoire. Arch Psychol 1944:286–356.
[78] Pena-Casanova J, Quinones-Ubeda S, Gramunt-Fombuena N, Quin-
tana-Aparicio M, Aguilar M, Badenes D, et al. Spanish Multicenter
Normative Studies (NEURONORMA Project): norms for verbal
fluency tests. Arch Clin Neuropsychol 2009;24:395–411.
[79] Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and
education for two measures of verbal fluency: FAS and animal
naming. Arch Clin Neuropsychol 1999;14:167–77.
[80] Pena-Casanova J, Quinones-Ubeda S, Quintana-Aparicio M,
Aguilar M, Badenes D, Molinuevo JL, et al. Spanish Multicenter
Normative Studies (NEURONORMA Project): norms for verbal
span, visuospatial span, letter and number sequencing, trail making
test, and symbol digit modalities test. Arch Clin Neuropsychol
2009;24:321–41.
[81] Cacho J, Garcıa-Garcıa R, Arcaya J, Gay J, Guerrero-Peral AL,
Gomez-Sanchez JC, et al. The “clock drawing test” in healthy elderly
people. Rev Neurol 1996;24:1525–8.
[82] Pena-Casanova J, Quinones-Ubeda S, Gramunt-Fombuena N,
Aguilar M, Casas L, Molinuevo JL, et al. Spanish Multicenter
Normative Studies (NEURONORMA Project): norms for Boston
naming test and token test. Arch Clin Neuropsychol 2009;24:343–54.
[83] Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test. 2nd
ed. Philadelphia: Lippincott Williams & Wilkins; 2001.
[84] Goodglass H, Kaplan E, Barresi B. Evaluacion de la afasia y de trans-
tornos relacionados. The assessment of aphasia and related disorders.
3rd ed. Editorial Medica Panamericana; 2005.
[85] Pena-Casanova J, Quintana-Aparicio M, Quinones-Ubeda S,
Aguilar M, Molinuevo JL, Serradell M, et al. Spanish Multicenter
Normative Studies (NEURONORMA Project): norms for the visual
object and space perception battery-abbreviated, and judgment of
line orientation. Arch Clin Neuropsychol 2009;24:355–70.
[86] Poppelreuter W. Die Psychischen Schaedungen durch Kopfschuss in
Kriege 1914-1916. Leipzig: Voss; 1917.
[87] Cummings JL, Mega M, Gray K, Rosenberg-Thompson S,
Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehen-
sive assessment of psychopathology in dementia. Neurology 1994;
44:2308–14.
[88] Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull
1988;24:709–11.
[89] Teunisse S, DerixMM. The interview for deterioration in daily living
activities in dementia: agreement between primary and secondary
caregivers. Int Psychogeriatrics 1997;9:155–62.
[90] Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deteriora-
tion Scale for assessment of primary degenerative dementia. Am J
Psychiatry 1982;139:1136–9.
[91] Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new
clinical scale for the staging of dementia. Br J Psychiatry 1982;
140:566–72.
D. Alcolea et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 597-609 609[92] Knopman DS, Kramer JH, Boeve BF, Caselli RJ, Graff-Radford NR,
Mendez MF, et al. Development of methodology for conducting clin-
ical trials in frontotemporal lobar degeneration. Brain 2008;
131:2957–68.
[93] Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-
Martin P, et al. Movement Disorder Society-sponsored revision of the
Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale pre-
sentation and clinimetric testing results. Mov Disord 2008;
23:2129–70.
[94] Elahi FM,Miller BL. A clinicopathological approach to the diagnosis
of dementia. Nat Rev Neurol 2017;13:457–76.
[95] Mioshi E, Hsieh S, Savage S, Hornberger M, Hodges JR. Clinical
staging and disease progression in frontotemporal dementia.
Neurology 2010;74:1591–7.
[96] Turro-Garriga O, Hermoso Contreras C, Olives Cladera J, Mioshi E,
Pelegrın Valero C, Olivera Pueyo J, et al. Adaptation and validation of
a Spanish-language version of the Frontotemporal Dementia Rating
Scale (FTD-FRS). Neurologia 2017;32:290–9.
[97] Niven E, Newton J, Foley J, Colville S, Swingler R, Chandran S, et al.
Validation of the Edinburgh Cognitive and Behavioural Amyotrophic
Lateral Sclerosis Screen (ECAS): A cognitive tool for motor disor-
ders. Amyotroph Lateral Scler Front Degener 2015;16:172–9.
[98] Mora JS, Salas T, Fernandez MC, Rodrıguez-Castillo V, Marın S,
Chaverri D, et al. Spanish adaptation of the edinburgh cognitive
and behavioral amyotrophic lateral sclerosis screen (ECAS). Amyo-
troph Lateral Scler Front Degener 2018;19:74–9.
[99] Leyton CE, Villemagne VL, Savage S, Pike KE, Ballard KJ,
Piguet O, et al. Subtypes of progressive aphasia: application of the In-
ternational Consensus Criteria and validation using b-amyloid imag-
ing. Brain 2011;134:3030–43.
[100] Gil-Navarro S, Llado A, Rami L, Castellvı M, Bosch B, Bargallo N,
et al. Neuroimaging and biochemical markers in the three variants of
primary progressive aphasia. Dement Geriatr Cogn Disord 2013;
35:106–17.[101] Strand EA, Duffy JR, Clark HM, Josephs K. The Apraxia of Speech
Rating Scale: a tool for diagnosis and description of apraxia of
speech. J Commun Disord 2014;51:43–50.
[102] Rami L, Serradell M, Bosch B, Caprile C, Sekler A, Villar A, et al.
Normative data for the Boston Naming Test and the Pyramids and
Palm Trees Test in the elderly Spanish population. J Clin Exp Neuro-
psychol 2008;30:1–6.
[103] Howard D, Patterson K. The Pyramids and Palm Trees Test : ATest of
Semantic Access from Words and Pictures. Pearson Assessment;
1992.
[104] Molto JM, Igual B, Pastor I, Gonzalez-Aniorte R, Asensio M. Gon-
zales-Montalvo word accentuation test in a healthy population. Rev
Neurol 1997;25:2062–3.
[105] Delis DC, Kaplan E, Kramer JH, Psychological Corporation.
Delis-Kaplan Executive Function System (D-KEFS): Flexibility
of Thinking, Concept Formation, Problem Solving, Planning,
Creativity, Impluse Control, Inhibition. Psychological Corp;
2001.
[106] Pena-Casanova J, Quinones-Ubeda S, Gramunt-Fombuena N,
Quintana M, Aguilar M, Molinuevo JL, et al. Spanish Multicenter
Normative Studies (NEURONORMA Project): Norms for the Stroop
Color-Word Interference Test and the Tower of London-Drexel. Arch
Clin Neuropsychol 2009;24:413–29.
[107] Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal
Assessment Battery at bedside. Neurology 2000;55:1621–6.
[108] Kertesz A, Davidson W, Fox H. Frontal behavioral inventory: diag-
nostic criteria for frontal lobe dementia. Can J Neurol Sci 1997;
24:29–36.
[109] Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L. The Lille
apathy rating scale: validation of a caregiver-based version.MovDis-
ord 2008;23:845–9.
[110] Wear HJ, Wedderburn CJ, Mioshi E, Williams-Gray CH, Mason SL,
Barker RA, et al. The Cambridge Behavioural Inventory revised. De-
ment Neuropsychol 2008;2:102–7.
